gazyvaro
roche registration gmbh - obinutuzumab - leukemi, lymfocytisk, kronisk, b-cell - antineoplastiska medel - kronisk lymfatisk leukemi (kll)gazyvaro i kombination med chlorambucil är indicerat för behandling av vuxna patienter med tidigare obehandlad kronisk lymfatisk leukemi (kll) och med sjukdomstillstånd vilket gör dem olämpliga för full dos fludarabinkombinationer baserad terapi (se avsnitt 5. follikulärt lymfom (fl)gazyvaro i kombination med kemoterapi, följt av gazyvaro underhållsbehandling för patienter att nå ett svar, är indicerat för behandling av patienter med tidigare obehandlad avancerad follikulära lymfom. gazyvaro i kombination med bendamustine följt av gazyvaro underhåll är indicerat för behandling av patienter med follikulärt lymfom (fl) som inte svarade eller som gått under eller upp till 6 månader efter behandling med rituximab eller en rituximab-innehållande regim.
calquence
astrazeneca ab - acalabrutinib - leukemi, lymfocytisk, kronisk, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastiska medel - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiska medel - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemi, lymfocytisk, kronisk, b-cell - antineoplastiska medel - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
ribovact 2,5 mg/ml pulver till koncentrat till infusionsvätska, lösning
astellas pharma gmbh - bendamustinhydroklorid - pulver till koncentrat till infusionsvätska, lösning - 2,5 mg/ml - mannitol hjälpämne; bendamustinhydroklorid 2,5 mg aktiv substans - bendamustin
ribovact 2,5 mg/ml pulver till koncentrat till infusionsvätska, lösning
orifarm ab - bendamustinhydroklorid - pulver till koncentrat till infusionsvätska, lösning - 2,5 mg/ml - mannitol hjälpämne; bendamustinhydroklorid 2,5 mg aktiv substans - bendamustin
bendamustin actavis 2,5 mg/ml pulver till koncentrat till infusionsvätska, lösning
actavis group ptc ehf. - bendamustinhydroklorid - pulver till koncentrat till infusionsvätska, lösning - 2,5 mg/ml - mannitol hjälpämne; bendamustinhydroklorid 2,5 mg aktiv substans
bendamustine accord 2,5 mg/ml pulver till koncentrat till infusionsvätska, lösning
accord healthcare b.v. - bendamustinhydroklorid - pulver till koncentrat till infusionsvätska, lösning - 2,5 mg/ml - bendamustinhydroklorid 2,5 mg aktiv substans; mannitol hjälpämne